Marinus Pharmaceuticals, Inc. (MRNS) Financial Statements (2024 and earlier)

Company Profile

Business Address 5 RADNOR CORPORATE CENTER SUITE 500
RADNOR, PA 19087
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments240,551122,927139,98391,68272,72553,392
Cash and cash equivalents240,551122,927138,50990,94367,72733,531
Short-term investments  1,4747394,99819,861
Receivables6,3482,629    
Inventory, net of allowances, customer advances and progress billings77     
Inventory77     
Contract with customer, asset, after allowance for credit loss   1,646  
Other undisclosed current assets5,4026,1224,6382,4521,215978
Total current assets:252,378131,678146,26794,13473,94054,370
Noncurrent Assets
Property, plant and equipment4,2362,4991,9452,2651,2941,338
Long-term investments and receivables      4,964
Long-term investments      4,964
Other noncurrent assets2,9042,6632,2502,443  
Total noncurrent assets:7,1405,1624,1954,7081,2946,302
TOTAL ASSETS:259,518136,840150,46298,84275,23460,672
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities23,99719,33310,7298,0316,9092,544
Accounts payable4,4613,1262,2112,7632,472927
Accrued liabilities19,53616,2078,5185,2684,4371,617
Debt      
Other undisclosed current liabilities1,02021,233    
Total current liabilities:25,01740,56610,7298,0316,9092,544
Noncurrent Liabilities
Long-term debt and lease obligation71,01840,809    
Long-term debt, excluding current maturities71,01840,809    
Liabilities, other than long-term debt2,6821,9792,5343,042 120
Accounts payable and accrued liabilities1,3411,9792,5343,042 120
Operating lease, liability1,341   
Other undisclosed noncurrent liabilities44,801     
Total noncurrent liabilities:118,50142,7882,5343,042 120
Total liabilities:143,51883,35413,26311,0736,9092,664
Temporary equity, carrying amount    28,200  
Equity
Equity, attributable to parent116,00053,486137,19959,56968,32558,008
Preferred stock 4,0434,3024,469   
Common stock503737875341
Additional paid in capital542,428459,852444,622295,056249,727202,790
Accumulated other comprehensive loss    (2)(96)
Accumulated deficit(430,521)(410,705)(311,929)(235,574)(181,453)(144,727)
Total equity:116,00053,486137,19959,56968,32558,008
TOTAL LIABILITIES AND EQUITY:259,518136,840150,46298,84275,23460,672

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues25,47815,345    
Cost of revenue(1,209)(1,478)    
Cost of goods and services sold  (1,478)    
Gross profit:24,26913,867    
Operating expenses(137,057)(110,798)(69,655)(54,422)(37,179)(19,043)
Other undisclosed operating income   1,718   
Operating loss:(112,788)(96,931)(67,937)(54,422)(37,179)(19,043)
Nonoperating income (expense)(342)1,667459309532332
Investment income, nonoperating2,35480496362533352
Gain, foreign currency transaction, before tax  930    
Other nonoperating income (expense)(2,696)657(37)(53)(1)(20)
Interest and debt expense(10,672)(2,582)   (159)
Other undisclosed income (loss) from continuing operations before equity method investments, income taxes   3(8)(79)(28)
Loss from continuing operations before equity method investments, income taxes:(123,802)(97,846)(67,475)(54,121)(36,726)(18,898)
Other undisclosed income (loss) from continuing operations before income taxes 107,375(930)    
Loss from continuing operations before income taxes:(16,427)(98,776)(67,475)(54,121)(36,726)(18,898)
Income tax expense(3,389)     
Loss from continuing operations:(19,816)(98,776)(67,475)(54,121)(36,726)(18,898)
Loss before gain (loss) on sale of properties:(98,776)(67,475)(54,121)(36,726)(18,898)
Other undisclosed net loss      
Net loss attributable to parent:(19,816)(98,776)(67,475)(54,121)(36,726)(18,898)
Preferred stock dividends and other adjustments   (8,880)   
Other undisclosed net income available to common stockholders, basic      
Net loss available to common stockholders, diluted:(19,816)(98,776)(76,355)(54,121)(36,726)(18,898)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(19,816)(98,776)(67,475)(54,121)(36,726)(18,898)
Comprehensive loss:(19,816)(98,776)(67,475)(54,121)(36,726)(18,898)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent    94(96)
Comprehensive loss, net of tax, attributable to parent:(19,816)(98,776)(67,475)(54,121)(36,632)(18,994)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: